Bispecific Antibodies

#Antibodies #Bispecific Antibodies #Interview #Oncology #Therapeutic Antibodies

Dual-targeted antibody innovations for cancer treatment

David Epstein, Chair & Chief Executive Officer of Ottimo Pharma, speaks to Megan Thomas about innovation in therapeutic antibody development, in the context of the company’s accelerated development of a novel PD1/VEGFR2 bifunctional antibody planned to enter the clinic in 2025, designed as a dual-pathway, single agent, IgG therapy targeting… Read More

#Cancer Research #Exclusive Content

#Antibody drug conjugate (ADC) #Bispecific Antibodies #Breast cancer #Oncology #Solid tumours

This week in drug discovery (20-24 January) 

News round-up for 20-24 January by DDW Senior Digital Content Editor Diana Spencer. In the same week that Phesi revealed that breast cancer is the most studied disease for the fourth year in a row, there have been a number of breakthroughs in the treatment of solid tumours,… Read More

#News

Non-small cell lung cancer
#Bispecific Antibodies #European Commission #Johnson & Johnson #Non-small cell lung cancer (NSCLC) #Oncology

Bispecific antibody combo for NSCLC could extend life by a year

The European Commission (EC) has approved a Marketing Authorisation (MA) for Lazcluze (lazertinib), in combination with Rybrevant (amivantamab).  It is approved for the first-line treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions (ex19del) or exon… Read More

#News #Regulatory

Bispecific antibodies
#Bispecific Antibodies #Bispecific therapeutics #Daiichi Sankyo #Oncology #Partnership #Solid tumours

Partners invite proposals for multi-functional biologics research

Daiichi Sankyo and German research institute BioMed X have agreed a new partnership to advance the development of bi- and multi-specific biologics for treating solid tumours.  The new project, entitled ‘New Strategies for Targeting of Solid Tumours with Multi-Specific Biologics (MTT; Multi-Specific Targeting of Tumours)’, will be… Read More

#Business & Investment #News

Antibody drug conjugate
#Allink Biotherapeutics #Antibody drug conjugate (ADC) #Bispecific Antibodies #Financing

Allink raises $42m for bispecific antibody and ADC pipeline

Biotechnology company Allink Biotherapeutics has successfully completed a $42 million Series A financing.   The financing round was led by Lanchi Ventures, with participation new investors including Yuanbio Venture Capital, Legend Capital and C&D Emerging Industry Equity Investment, alongside strong support from existing shareholders Gaorong Ventures and Med-Fine… Read More

#Business & Investment #News

FDA
#Bispecific Antibodies #FDA #Jazz Pharmaceuticals #Oncology

Bispecific antibody gets accelerated FDA approval for biliary tract cancer

The Food and Drug Administration (FDA) has granted accelerated approval to Jazz Pharmacuticals’ zanidatamab-hrii (Ziihera) a bispecific HER2-directed antibody.  It is approved for previously treated, unresectable or metastatic HER2-positive (IHC 3+) biliary tract cancer (BTC), as detected by an FDA-approved test.  The FDA… Read More

#News #Regulatory

Bispecific antibodies
#Antibodies #Antibody engineering #Bispecific Antibodies #EpiBiologics #PEGS Europe

Data shows disease-selective extracellular protein degradation 

EpiBiologics presented new data demonstrating the unique capabilities of its EpiTAC platform at the 16th Annual PEGS Europe conference (November 5-7, 2024 in Barcelona, Spain) and the 2024 Antibody Engineering and will be presenting again at Therapeutics US conference (December 15-18, 2024 in San Diego, California).  … Read More

#News

Therapeutic antibodies
#Bispecific Antibodies #Interview #Lymphoma #Oncology

Q&A: Targeting difficult to treat lymphomas with a bispecific antibody

DDW Editor Reece Armstrong speaks to Tahi Ahmadi, MD, PhD, Executive Vice President & Chief Medical Officer, Head of Experimental Medicines, Genmab & Jacqueline Nielsen, PhD, Therapeutic Head, Hematology, AbbVie, about the recommendation and the development of epcoritamab. Earlier this year, the European Medicines Agenecy’s (EMA) Committee for Medicinal Products… Read More

#Cancer Research #Exclusive Content

FDA headquarters
#Bispecific Antibodies #FDA #Oncology #Orphan drugs #Phanes Therapeutics

Neuroendocrine carcinoma drug granted orphan status

Phanes Therapeutics’ PT217 has received orphan drug designation (ODD) for neuroendocrine carcinoma (NEC) from the US Food and Drug Administration (FDA). PT217 is a first-in-class bispecific antibody targeting delta-like ligand 3 (DLL3) and cluster of differentiation 47 (CD47) being developed for patients with NEC. Read More

#Cancer Research #News #Regulatory

Woman with a nose bleed
#Bispecific Antibodies #Events #Haemophilia #Novo Nordisk #Phase III trial

Bispecific antibody successfully reduced bleeds in haemophilia A

Novo Nordisk has announced results from the Phase III FRONTIER2 trial of 254 adults and adolescents aged 12 years and over with haemophilia A, with and without inhibitors. The trial assessed both once-weekly and once-monthly prophylactic treatment with the investigational treatment Mim8. The data… Read More

#News

Therapeutic antibodies
#Antibody drug conjugate (ADC) #Bispecific Antibodies #Drug discovery #eBook #Therapeutic Antibodies

eBook: The impact of therapeutic antibody discovery

A new eBook, sponsored by Sino Biological, is now available for download entitled ‘The impact of therapeutic antibody discovery’. The first monoclonal antibody (mAb), Orthoclone, was approved in 1986 to help prevent rejection in organ transplantation. Since then, the US Food and Drug… Read More

#News

The impact of therapeutic antibody discovery
#Antibody drug conjugate (ADC) #Bispecific Antibodies #Drug discovery #eBook #Therapeutic Antibodies

The impact of therapeutic antibody discovery

This eBook explores the challenges and opportunities in the therapeutic antibody market, the range of applications for these therapies and the move towards more targeted and effective next-generation antibody treatments. Download this exclusive eBook to learn more about: How artificial intelligence and machine learning are benefitting antibody discovery and design… Read More

#DDW eBooks #Intelligence

Bispecific antibodies
#AbbVie #ASCO #Bispecific Antibodies #Follicular lymphoma #Genmab #Haematology #Oncology

95% response to bispecific antibody in follicular lymphoma

Previously untreated follicular lymphoma (FL) patients who received epcoritamab with rituximab-lenalidomide (R2) had a 95% overall response rate (ORR), according to preliminary trial data. The results of two ongoing Phase I/II clinical trials evaluating cancer immunotherapy epcoritamab, a T-cell engaging bispecific antibody, were shared at… Read More

#Cancer Research #News #Trending News

#Antibodies #Bispecific Antibodies #FDA #Monoclonal antibodies #Neuroscience #Oncology

New DDW Highlights podcast: 11 March 2024

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  It was antibodies hitting the headlines this week, with the discovery of antibodies with… Read More

#News